ProteoGenix

About ProteoGenix

ProteoGenix, established in 2003, operates as a Contract Research Organization (CRO) specializing in integrated solutions for biotherapeutics and diagnostics. The company was co-founded by Philippe Funfrock, who serves as CEO, and Raphaël Hopfner, the Chief Scientific Officer. Funfrock, with an MBA from the University of Maryland, brought an entrepreneurial drive, while Hopfner's scientific background, including the co-discovery of the human protein UHRF1, spurred the initial idea to develop a cancer diagnosis marker screening platform. This encounter led to the formation of ProteoGenix, initially aimed at creating diagnostic assays and biotherapeutics based on their own protein discoveries.

The firm serves pharmaceutical and biotech companies, as well as Chief Marketing Officers (CMOs) and Contract Development and Manufacturing Organizations (CDMOs), by providing end-to-end support from early-stage R&D to preclinical phases. Its business model is centered on offering custom services and selling catalog products. The company generates revenue by providing a comprehensive suite of services that guide clients from discovery to Investigational New Drug (IND) applications. With a global presence in France and the US, ProteoGenix supports researchers worldwide.

ProteoGenix's core offerings are structured around six complementary areas: gene synthesis, peptide synthesis, recombinant protein production, monoclonal and polyclonal antibody development, antibody engineering, and bioprocess development. The company provides custom synthesis of proteins, peptides, and genes, along with both monoclonal and polyclonal antibody production using technologies like hybridoma and phage display. A key product is their proprietary XtenCHO™ transient expression system, a cell line noted for high productivity in protein and antibody production. Furthermore, ProteoGenix maintains a vast catalog of over 200,000 products, including recombinant proteins, primary and secondary antibodies, and ELISA assay kits.